I-Mab Unveils Strategic Changes, Hong Kong IPO Plans, and Rebrands to NovaBridge Biosciences

I-Mab, a global biotechnology platform company, announced a shift in strategy to focus on business development and translational clinical development aimed at getting innovative medicines to patients quickly.

The company shared its intent to conduct an initial public offering (IPO) in Hong Kong, aiming to increase access to global capital through listings on both NASDAQ and the Hong Kong Stock Exchange.…

This data comes from the ChinaPulse.com media intelligence and smart news insights monitoring platform.